Targeted Disruption of USP14 and UCHL5 with the Novel Deubiquitinase Enzyme (DUB) Inhibitor, VLX1570, Induces Immense Proteotoxicity and Cell Death in Malignant Plasma Cells
Aneel Paulus(WinnMed), Kasyapa S. Chitta(Mayo Clinic in Florida), Maja K. Blake(Jacksonville College), Robert A. Kyle(Mayo Clinic), Stig Linder(Karolinska Institutet), Anne J. Novak(Mayo Clinic), Peter Martin(Northwestern University), Sikander Ailawadhi(Jacksonville College), Sharoon Akhtar(Mayo Clinic in Florida), Stephen M. Ansell(Mayo Clinic), Asher Chanan‐Khan(WinnMed), Morton Coleman(Cornell University), Morie A. Gertz(Medical University of South Carolina)
Cited by 6
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k